Single Dose of Bisphosphonate Preserves Gains in Bone Mass Following Cessation of Sclerostin Antibody in Brtl/+ Osteogenesis Imperfecta Model

Sclerostin antibody has demonstrated a bone-forming effect in pre-clinical models of osteogenesis imperfecta, where mutations in collagen or collagen-associated proteins often result in high bone fragility in pediatric patients. Cessation studies in osteoporotic patients have demonstrated that scler...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Bone
Päätekijät: Perosky, Joseph E., Khoury, Basma M., Jenks, Terese N., Ward, Ferrous S., Cortright, Kai, Meyer, Bethany, Barton, David K., Sinder, Benjamin P., Marini, Joan C., Caird, Michelle S., Kozloff, Kenneth M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5077648/
https://ncbi.nlm.nih.gov/pubmed/27641475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2016.09.013
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia